Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
10.1007/s10147-021-01869-0
Saved in:
Main Authors: | Chang, Gee-Chen, Lam, David Chi-Leung, Tsai, Chun-Ming, Chen, Yuh-Min, Shih, Jin-Yuan, Aggarwal, Shyam, Wang, Shuhang, Kim, Sang-We, Kim, Young-Chul, Wahid, Ibrahim, Li, Rubi, Lim, Darren Wan-Teck, Sriuranpong, Virote, Chan, Raymond Tsz-Tong, Lorence, Robert M, Carriere, Philippe, Raabe, Christina, Cseh, Agnieszka, Park, Keunchil |
---|---|
Other Authors: | DUKE-NUS MEDICAL SCHOOL |
Format: | Article |
Language: | English |
Published: |
SPRINGER JAPAN KK
2022
|
Subjects: | |
Online Access: | https://scholarbank.nus.edu.sg/handle/10635/218517 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Language: | English |
Similar Items
-
Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021) -
First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022) -
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022) -
Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020) -
The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients
by: Tan E.K., et al.
Published: (2018)